Shares of Danish pharmaceutical giant Novo-Nordisk A/S experienced a significant 5.27% drop on Tuesday intraday trading session, amid concerns over a potential slowdown in the sales growth of its blockbuster GLP-1 diabetes and weight-loss drugs.
The stock plunge was triggered by news from rival company Eli Lilly, which warned that its fourth-quarter 2024 revenue from the GLP-1 drug market (known as the "incretin market") is expected to be approximately $400 million lower than previously anticipated. While Eli Lilly's overall sales for 2024 and 2025 still showed strong growth, the potential slowdown in the lucrative GLP-1 segment raised concerns among investors.
Analysts speculate that Novo-Nordisk, as a key player in the GLP-1 market, could be impacted by this slowdown, leading to a sell-off in its shares. Notably, Eli Lilly stated that it did not gain any additional market share in the fourth quarter of 2024, implying that Novo-Nordisk's market position remained stable during that period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.